サマリー

APACの急性骨髄性白血病（AML）治療市場 2022-2026年
Technavioは、APACの急性骨髄性白血病（AML）治療市場を監視しており、2022年から2026年の間に27703万ドル、予測期間中に12.83％のCAGRで進行することが予測される。当レポートでは、APACの急性骨髄性白血病（AML）治療市場について、市場規模や予測、動向、成長ドライバー、課題などの全体的な分析に加え、約25社のベンダーを網羅したベンダー分析も行っています。
現在の市場シナリオ、最新動向とドライバー、市場全体の環境に関する最新の分析を提供しています。市場は、APAC地域における急性骨髄性白血病の高い発症率と薬理学および分子生物学の進歩によって牽引されています。また、急性骨髄性白血病の発症率の高さは、市場の成長をも押し上げると予想されます。
APACの急性骨髄性白血病（AML）治療市場の分析には、タイプ別セグメントと地理的状況が含まれます。
TechnavioのAPACの急性骨髄性白血病（AML）治療市場は、以下のように区分されています。
タイプ別
- 化学療法
- 幹細胞移植
- その他
地域別状況
- 中国
- 日本
- インド
- APACの残りの地域
本調査では、今後数年間におけるAPAC地域の急性骨髄性白血病（APAC）治療市場の成長を牽引する主な要因の1つとして、ジェネリック医薬品の採用が増加していることを挙げています。
Technavio社は、複数のソースからのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細図を提示します。APACの急性骨髄性白血病（APAC )治療市場に関する当レポートは、以下の分野を対象としています。
- 急性骨髄性白血病（APAC ）治療市場のサイジング
- 急性骨髄性白血病(APAC )治療市場予測
- 急性骨髄性白血病（APAC）治療市場の産業分析
Technavioの強固なベンダー分析は、顧客が市場での地位を向上できるように設計されており、これに沿って本レポートでは、APACの急性骨髄性白血病（APAC ）治療市場の主要ベンダー（AbbVie Inc, Agios Inc, Astellas Pharma Inc, Bristol Myers Squibb Co, Daiichi Sankyo Co, Ltd.など）について詳細に分析している。ホフマン・ラ・ロシュ社、グラクソ・スミスクライン社、ノバルティス社、ファイザー社、テバ・ファーマシューティカル・インダストリーズ社（以下、「Teva社」）です。また、APACの急性骨髄性白血病（APAC ）治療市場の分析レポートには、今後の動向と市場成長に影響を与える課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含む、一次情報と二次情報の客観的な組み合わせを使用して実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/acute-myeloid-leukemia-aml-treatment-market-industry-in-apac-analysis をご覧ください。
Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数のソースからのデータを調査、合成、総括する方法で、市場の詳細なイメージを提示します。また、業界の主要なインフルエンサーを特定することにより、市場の様々な側面を提示します。提示されるデータは、包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、定性的および定量的調査を用いた詳細なベンダー選定方法および分析を提供します。

ページTOPに戻る

目次

• 1. Executive Summary
o 1.1 Market Overview
o Exhibit 01: Key Finding 1
o Exhibit 02: Key Finding 2
o Exhibit 03: Key Finding 3
o Exhibit 04: Key Finding 5
o Exhibit 05: Key Finding 6
o Exhibit 06: Key Finding 7
• 2. Market Landscape
o 2.1 Market ecosystem
o Exhibit 07: Parent market
o Exhibit 08: Market Characteristics
o 2.2 Value Chain Analysis
o Exhibit 09: Value chain analysis: Pharmaceuticals
o 2.2.1 Research and development (R&D) and drug discovery
o 2.2.2 Integration and product development
o 2.2.3 Manufacturing
o 2.2.4 Outbound logistics
o 2.2.5 Marketing and sales
o 2.2.6 Support activities
o 2.2.7 Innovation
• 3. Market Sizing
o 3.1 Market definition
o Exhibit 10: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 11: Market segments
o 3.3 Market size 2020
o 3.4 Market outlook: Forecast for 2020 - 2025
o 3.4.1Estimating growth rates for emerging and high-growth markets
o 3.4.2 Estimating growth rates for mature markets
o Exhibit 12: Global - Market size and forecast 2021 - 2026 (million $)
o Exhibit 13: Global market: Year-over-year growth 2021 - 2026 (%)
• 4. Five Forces Analysis
o 4.1 Five Forces Summary
o Exhibit 14: Five forces analysis 2021 - 2026
o 4.2 Bargaining power of buyers
o Exhibit 15: Bargaining power of the buyer
o 4.3 Bargaining power of suppliers
o Exhibit 16: Bargaining power of the supplier
o 4.4 Threat of new entrants
o Exhibit 17: Threat of new entrants
o 4.5 Threat of substitutes
o Exhibit 18: Threat of substitutes
o 4.6 Threat of rivalry
o Exhibit 19: Threat of rivalry
o 4.7 Market condition
o Exhibit 20: Market condition - Five forces 2021
• 5. Market Segmentation by Type
o 5.1 Market segments
o Exhibit 21: Type- Market share 2021-2026 (%)
o 5.2 Comparison by Type
o Exhibit 22: Comparison by Type
o 5.3 Chemotherapy - Market size and forecast 2021-2026
o Exhibit 23: Chemotherapy- Market size and forecast 2021-2026 ($ billion)
o Exhibit 24: Chemotherapy- Year-over-year growth 2021-2026 (%)
o 5.4 Stem cell transplantation - Market size and forecast 2021-2026
o Exhibit 25: Stem cell transplantation - Market size and forecast 2021-2026 ($ billion)
o Exhibit 26: Stem cell transplantation- Year-over-year growth 2021-2026 (%)
o 5.5 Others - Market size and forecast 2021-2026
o Exhibit 27: Others - Market size and forecast 2021-2026 ($ billion)
o Exhibit 28: Others- Year-over-year growth 2021-2026 (%)
o 5.6 Market opportunity by Type
o Exhibit 29: Market opportunity by Type
• 6. Customer landscape
o Technavio€™s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
o Exhibit 30: Customer landscape
• 7 Geographic Landscape
o 7.1 Geographic segmentation
o Exhibit 31: Market share By Geographical Landscape 2021-2026 (%)
o 7.2 Geographic comparison
o Exhibit 32: Geographic comparison
o 7.3 China - Market size and forecast 2021-2026
o Exhibit 33: China - Market size and forecast 2021-2026 ($ million)
o Exhibit 34: China - Year-over-year growth 2021-2026 (%)
o 7.4 Japan - Market size and forecast 2021-2026
o Exhibit 35: Japan - Market size and forecast 2021-2026 ($ million)
o Exhibit 36: Japan - Year-over-year growth 2021-2026 (%)
o 7.5 India - Market size and forecast 2021-2026
o Exhibit 37: India - Market size and forecast 2021-2026 ($ million)
o Exhibit 38: India - Year-over-year growth 2021-2026 (%)
o 7.6 Rest of APAC - Market size and forecast 2021-2026
o Exhibit 39: Rest of APAC - Market size and forecast 2021-2026 ($ million)
o Exhibit 40: Rest of APAC - Year-over-year growth 2021-2026 (%)
o 7.7 Key leading countries
o Exhibit 41: Key leading countries
o 7.8 Market opportunity By Geographical Landscape
o Exhibit 42: Market opportunity By Geographical Landscape ($ million)
• 8. Drivers, Challenges, and Trends
o 8.1 Market drivers
o 8.1.1 High incidence of acute myeloid leukemia
o 8.1.2 Advancements in pharmacology and molecular biology in APAC
o 8.1.3 Rising adoption of generic drugs
o 8.2 Market challenges
o 8.2.1 Lack of adequate healthcare infrastructure in developing nations
o 8.2.2 Complications related to chemotherapy
o 8.2.3 High cost of treatment
o Exhibit 43: Impact of drivers and challenges
o 8.3 Market trends
o 8.3.1 CAR T-cell therapy for AML
o 8.3.2 Approval of new treatment methods
o 8.3.3 Increase in awareness programs
• 9. Vendor Landscape
o 9.1 Overview
o Exhibit 44: Vendor landscape
o 9.2 Landscape disruption
o Exhibit 45: ?Landscape disruption?
o Exhibit 46: Industry Risk
• 10. Vendor Analysis
o 10.1 Vendors Covered
o Exhibit 47: Vendor Landscape
o 10.2 Market positioning of vendors
o Exhibit 48: ?Market positioning of vendors?
o 10.3 AbbVie Inc.
o Exhibit 49: AbbVie Inc. - Overview
o Exhibit 50: AbbVie Inc. - Business segments
o Exhibit 51: AbbVie Inc. - Key offerings
o Exhibit 52: AbbVie Inc. - Segment focus
o 10.4 Agios Inc.
o Exhibit 53: Agios Inc. - Overview
o Exhibit 54: Agios Inc. - Business segments
o Exhibit 55: Agios Inc. - Key offerings
o Exhibit 56: Agios Inc. - Segment focus
o 10.5 Astellas Pharma Inc.
o Exhibit 57: Astellas Pharma Inc. - Overview
o Exhibit 58: Astellas Pharma Inc. - Product and service
o Exhibit 59: Astellas Pharma Inc. - Key offerings
o 10.6 Bristol Myers Squibb Co.
o Exhibit 60: Bristol Myers Squibb Co. - Overview
o Exhibit 61: Bristol Myers Squibb Co. - Product and service
o Exhibit 62: Bristol Myers Squibb Co. - Key offerings
o 10.7 Daiichi Sankyo Co. Ltd.
o Exhibit 63: Daiichi Sankyo Co. Ltd. - Overview
o Exhibit 64: Daiichi Sankyo Co. Ltd. - Business segments
o Exhibit 65: Daiichi Sankyo Co. Ltd. - Key offerings
o Exhibit 66: Daiichi Sankyo Co. Ltd. - Segment focus
o 10.8 F. Hoffmann La Roche Ltd.
o Exhibit 67: F. Hoffmann La Roche Ltd. - Overview
o Exhibit 68: F. Hoffmann La Roche Ltd. - Business segments
o Exhibit 69: F. Hoffmann La Roche Ltd. - Key offerings
o Exhibit 70: F. Hoffmann La Roche Ltd. - Segment focus
o 10.9 GlaxoSmithKline Plc
o Exhibit 71: GlaxoSmithKline Plc - Overview
o Exhibit 72: GlaxoSmithKline Plc - Business segments
o Exhibit 73: GlaxoSmithKline Plc - Key offerings
o Exhibit 74: GlaxoSmithKline Plc - Segment focus
o 10.10 Novartis AG
o Exhibit 75: Novartis AG - Overview
o Exhibit 76: Novartis AG - Business segments
o Exhibit 77: Novartis AG - Key offerings
o Exhibit 78: Novartis AG - Segment focus
o 10.11 Pfizer Inc.
o Exhibit 79: Pfizer Inc. - Overview
o Exhibit 90: Pfizer Inc. - Product and service
o Exhibit 91: Pfizer Inc. - Key News
o Exhibit 92: Pfizer Inc. - Key offerings
o 10.12 Teva Pharmaceutical Industries Ltd.
o Exhibit 93: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 94: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 95: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 96: Teva Pharmaceutical Industries Ltd. - Segment focus
• 11. Appendix
o 11.1 Scope of the report
o 11.1.1 ????Market definition
o 11.1.2 ????Objectives
o 11.1.3 ????Notes and caveats
o 11.2 Currency conversion rates for US$
o Exhibit 97: ?Currency conversion rates for US$?
o 11.3 Research Methodology
o Exhibit 98: ?Research Methodology
o Exhibit 99: ??Validation techniques employed for market sizing?
o Exhibit 100: ??Information sources
o 11.4 List of abbreviations
o Exhibit 101: List of abbreviations

•
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Parent market
• 8: Market characteristics
• 9: Offerings of vendors included in the market definition
• 10: Market segments
• 11: Global - Market size and forecast 2021 - 2026 ($ million)
• 12: Global market: Year-over-year growth 2021 - 2026 (%)
• 13: Five forces analysis 2021 & 2026
• 14: Bargaining power of buyers
• 15: Bargaining power of suppliers
• 16: Threat of new entrants
• 17: Threat of substitutes
• 18: Threat of rivalry
• 19: Market condition - Five forces 2021
• 20: Type - Market share 2021-2026 (%)
• 21: Comparison by Type
• 22: Chemotherapy - Market size and forecast 2021-2026 ($ million)
• 23: Chemotherapy - Year-over-year growth 2021-2026 (%)
• 24: Stem cell transplantation - Market size and forecast 2021-2026 ($ million)
• 25: Stem cell transplantation - Year-over-year growth 2021-2026 (%)
• 26: Others - Market size and forecast 2021-2026 ($ million)
• 27: Others - Year-over-year growth 2021-2026 (%)
• 28: Market opportunity by Type
• 29: Customer landscape
• 30: Market share By Geographical Landscape 2021-2026 (%)
• 31: Geographic comparison
• 32: China - Market size and forecast 2021-2026 ($ million)
• 33: China - Year-over-year growth 2021-2026 (%)
• 34: Japan - Market size and forecast 2021-2026 ($ million)
• 35: Japan - Year-over-year growth 2021-2026 (%)
• 36: India - Market size and forecast 2021-2026 ($ million)
• 37: India - Year-over-year growth 2021-2026 (%)
• 38: Rest of APAC - Market size and forecast 2021-2026 ($ million)
• 39: Rest of APAC - Year-over-year growth 2021-2026 (%)
• 40: Key leading countries
• 41: Market opportunity By Geographical Landscape ($ million)
• 42: Impact of drivers and challenges
• 43: Vendor landscape
• 44: Landscape disruption
• 45: Industry risks
• 46: Vendors covered
• 47: Market positioning of vendors
• 48: AbbVie Inc. - Overview
• 49: AbbVie Inc. - Business segments
• 50: AbbVie Inc. - Key offerings
• 51: AbbVie Inc. - Key customers
• 52: AbbVie Inc. - Segment focus
• 53: Agios Inc. - Overview
• 54: Agios Inc. - Business segments
• 55: Agios Inc. - Key offerings
• 56: Agios Inc. - Key customers
• 57: Agios Inc. - Segment focus
• 58: Astellas Pharma Inc. - Overview
• 59: Astellas Pharma Inc. - Product and service
• 60: Astellas Pharma Inc. - Key offerings
• 61: Astellas Pharma Inc. - Key customers
• 62: Astellas Pharma Inc. - Segment focus
• 63: Bristol Myers Squibb Co. - Overview
• 64: Bristol Myers Squibb Co. - Product and service
• 65: Bristol Myers Squibb Co. - Key offerings
• 66: Bristol Myers Squibb Co. - Key customers
• 67: Bristol Myers Squibb Co. - Segment focus
• 68: Daiichi Sankyo Co. Ltd. - Overview
• 69: Daiichi Sankyo Co. Ltd. - Business segments
• 70: Daiichi Sankyo Co. Ltd. - Key offerings
• 71: Daiichi Sankyo Co. Ltd. - Key customers
• 72: Daiichi Sankyo Co. Ltd. - Segment focus
• 73: F. Hoffmann La Roche Ltd. - Overview
• 74: F. Hoffmann La Roche Ltd. - Business segments
• 75: F. Hoffmann La Roche Ltd. - Key offerings
• 76: F. Hoffmann La Roche Ltd. - Key customers
• 77: F. Hoffmann La Roche Ltd. - Segment focus
• 78: GlaxoSmithKline Plc - Overview
• 79: GlaxoSmithKline Plc - Business segments
• 80: GlaxoSmithKline Plc - Key offerings
• 81: GlaxoSmithKline Plc - Key customers
• 82: GlaxoSmithKline Plc - Segment focus
• 83: Novartis AG - Overview
• 84: Novartis AG - Business segments
• 85: Novartis AG - Key offerings
• 86: Novartis AG - Key customers
• 87: Novartis AG - Segment focus
• 88: Pfizer Inc. - Overview
• 89: Pfizer Inc. - Product and service
• 90: Pfizer Inc. - Key offerings
• 91: Pfizer Inc. - Key customers
• 92: Pfizer Inc. - Segment focus
• 93: Teva Pharmaceutical Industries Ltd. - Overview
• 94: Teva Pharmaceutical Industries Ltd. - Business segments
• 95: Teva Pharmaceutical Industries Ltd. - Key offerings
• 96: Teva Pharmaceutical Industries Ltd. - Key customers
• 97: Teva Pharmaceutical Industries Ltd. - Segment focus
• 98: Currency conversion rates for US$
• 99: Research Methodology
• 100: Validation techniques employed for market sizing
• 101: Information sources
• 102: List of abbreviations